Sarcoma treatment in the era of molecular medicine
Publication year
2020Author(s)
Source
EMBO Molecular Medicine, 12, 11, (2020), article e11131ISSN
Publication type
Article / Letter to editor

Display more detailsDisplay less details
Organization
Medical Oncology
Journal title
EMBO Molecular Medicine
Volume
vol. 12
Issue
iss. 11
Subject
Radboudumc 9: Rare cancers RIMLS: Radboud Institute for Molecular Life SciencesAbstract
Sarcomas are heterogeneous and clinically challenging soft tissue and bone cancers. Although constituting only 1% of all human malignancies, sarcomas represent the second most common type of solid tumors in children and adolescents and comprise an important group of secondary malignancies. More than 100 histological subtypes have been characterized to date, and many more are being discovered due to molecular profiling. Owing to their mostly aggressive biological behavior, relative rarity, and occurrence at virtually every anatomical site, many sarcoma subtypes are in particular difficult-to-treat categories. Current multimodal treatment concepts combine surgery, polychemotherapy (with/without local hyperthermia), irradiation, immunotherapy, and/or targeted therapeutics. Recent scientific advancements have enabled a more precise molecular characterization of sarcoma subtypes and revealed novel therapeutic targets and prognostic/predictive biomarkers. This review aims at providing a comprehensive overview of the latest advances in the molecular biology of sarcomas and their effects on clinical oncology; it is meant for a broad readership ranging from novices to experts in the field of sarcoma.
This item appears in the following Collection(s)
- Academic publications [232297]
- Electronic publications [115529]
- Faculty of Medical Sciences [89118]
- Open Access publications [82812]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.